


NOXXON Pharma AG to provide Update on Three Development Programs based on proprietary Spiegelmer® Technology at the BIO International Conference on June 30th

Phase II study data for diabetic nephropathy, oncology and anemia of inflammation expected in 2012

Berlin, Germany, 27 June 2011 – NOXXON Pharma AG today will discuss progress of its three development programs including the on-going Phase Ib study of NOX-E36 for the treatment of diabetic nephropathy at the BIO International Convention BIO Business Forum from 9:45-10:00 AM (EDT) in the Capitol Hill room on June 30th.

Spiegelmers® are injectable therapeutics which are chemically and biologically stable, non-immunogenic and relatively easy to produce. The entire NOXXON Pharma pipeline is based on this proprietary technology. NOXXON also has an ongoing Phase I study of NOX-A12 which will be developed for treatment of hematological and solid tumors. Additionally, next month the company will begin its first clinical study of its Spiegelmer® NOX-H94 which will be developed for anemia of inflammation.



“We expect to have Phase II data for our three lead programs in 2012,” said Aram Mangasarian, Chief Business Officer of NOXXON Pharma AG. “This positions NOXXON as a strong candidate for international partnership opportunities in diabetes, oncology and anemia management.”

Both Dr. Aram Mangasarian and Dr. Sven Klussmann, Chief Scientific Officer of NOXXON Pharma will be available during the International BIO Convention for one-on-one meetings. To schedule, please contact NOXXON through the BIO Business Forum at:

<http://convention.bio.org/businessforum/>, or Emmanuelle Delabre at +49-30-726247-0, edelabre@noxxon.com.

About NOXXON Pharma AG

NOXXON Pharma AG is a biotechnology company developing a promising new class of therapeutics called Spiegelmers[®], which are oligonucleotides made from the L-stereoisomer of RNA. Spiegelmers[®] can be engineered to bind specifically to a precisely defined protein and lipid targets and have been shown to be potent inhibitors. Clinical and pre-clinical studies of Spiegelmers[®] to date have shown them to be exceptionally safe, well-tolerated, biologically stable and non-immunogenic. NOXXON has three programs in development, two of which, NOX-E36 and NOX-A12 have successfully completed their first Phase I clinical studies. The company has approximately 65 employees based at its headquarters in Berlin. NOXXON's investors are NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft (DEWB), Seventure Partners, The Dow Chemical Company, Dieckell Group, Oppenheim Asset Management Services, IBG Risikokapitalfonds, VC Fonds Berlin, CD Ventures and others.

About Spiegelmers[®]

Spiegelmers[®] (L-stereoisomer RNA oligonucleotides) are chemical entities based on synthetic mirror-image oligonucleotides which are highly selective for their pharmacological target and potent inhibitors of target function. They combine the benefits of small molecule drugs and biopharmaceuticals. Due to their unique mirror-image configuration Spiegelmers[®] are not metabolized and do not hybridize with native nucleic acids. Spiegelmers[®] also do not activate the innate immune response via toll-like receptors and showed an exceptionally favorable immunogenicity profile in pre-clinical testing

For more information, please visit:

<http://www.businesswire.com/portal/site/home/events/?eventName=2011-BIO-International-Convention&pressKitName=NOXXON-Pharma>

<http://www.noxxon.com/>

Editorial contact

Emmanuelle Delabre
+49-30-726247-0
edelabre@noxxon.com

Bio Convention contact

Aram Mangasarian
+49-30-726247-0
amangasarian@noxxon.com